Navigation Links
Delcath to Present at the 30th Annual Canaccord Global Growth Conference
Date:8/4/2010

ystemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, market acceptance and the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenu
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... comparable efficacy and safety for extended release and ... -- New findings from two double-blind ... pramipexole dihydrochloride tablets in an extended release, once-daily ... are being presented today at the American Academy ...
... Cover Therapeutic Delivery Across Blood-Brain BarrierNOVATO, Calif., April ... or the "Company") (OTC Bulletin Board: RPTP) today ... Office ("USPTO") has issued two Notices of Allowance ... titled " Methods of increasing delivery of active ...
Cached Medicine Technology:New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 2Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 3Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 4Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 5
(Date:4/23/2014)... NY, April 23, 2014Men whose testosterone falls below normal ... to be overweight and have heart disease and type ... identify testosterone-deficient men for further testing and possible treatment ... Men,s Health , a peer-reviewed publication from Mary Ann ... the Journal of Men,s Health website at ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... team of scientists led by a researcher from the ... National University of Singapore has identified the cancer specific ... up the possibility of developing new drugs for the ... , The research group, led by Dr Chan Shing ... the first time that a cancer-specific variant of a ...
(Date:4/23/2014)... the depletion of self-control, according to research published in ... for Psychological Science. , Self-control can be difficult ... on a boring textbook are hard things to do. ... Exerting self-control for a long period seems to "deplete" ... , "It is as if self-control is a limited ...
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... an interesting,snapshot of Minnesotans, changing driving habits, retail ... percent decline compared to sales in July 2007.,According ... motorists,bought 211,982,582 gallons of gasoline in July, compared ... the amount of ethanol-based,E85 sold during the same ...
... medical student in the country. That,s because the three-part ... delivered in a new way: by listening to a ... an Achilles heel in the medical field. , ... test know they don,t have this auditory skill," says Michael ...
... Trevino, master permanent make-up artist and educator joins Nouveau Cosmetique ... advance the education of permanent cosmetic professionals in the US. ... ... August 25, 2008 -- Nouveau Cosmetique USA, Inc., the exclusive ...
... (PTCB) Exhibits at this week,s National Association of Chain Drug ... solutions for enhanced patient safety and the benefits of pharmacy ... ... CA (PRWEB) August 25, 2008 - The https://www.ptcb.org/ ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held September 3-5, 2008 at the,Four ... and Chief Financial Officer of HMS Holdings Corp.,will present ... A live broadcast of the Company,s presentation can ...
... 96 on the, 2008 Inc. 500, with three-year sales growth ... ... Inc. magazine today ranked The,Coding Source No. 96 on its 27th ... list is the most,comprehensive look at the most important segment of the ...
Cached Medicine News:Health News:Listen up! 2Health News:Master Permanent Make-up Artist and Educator Sulema Trevino Joins Nouveau Cosmetique Team 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 3Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 3
Finally, a camera that sees the way you do!,Combined with the MicroLux DVR (Digital Video Recorder), the MicroLux Headlight Camera System gives you an entirely new way to visualize, edit, share and...
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... achieved using an increased tilt angle of ... bed. The patient preparation can be carried ... of an emergency the patient can be ... e.g. resuscitation purposes. The integrated neck support ...
... Magnes 1300 C is ideal for evaluating a ... other parts of the body. Often referred to ... including magnetocardiography, gastrointestinal tract, fetal, spinal cord and ... 1300 C, with its 67 detector coils, covers ...
Medicine Products: